Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;23(1):7-9.
doi: 10.1111/j.1755-148X.2009.00657.x. Epub 2009 Dec 2.

Anticipating drug resistance in the MAP kinase pathway

Ronen Marmorstein

Anticipating drug resistance in the MAP kinase pathway

Ronen Marmorstein. Pigment Cell Melanoma Res. 2010 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Drug resistant MEK1 mutations mapped onto the MEK1 structure in complex with ATP and the AZD6244 allosteric inhibitor. The structure was downloaded from the Protein Data Bank (accession number 3EQC). Only the N-terminal kinase domain of MEK1 is shown as a cartoon with the ATP and AZD6244 molecules shown as stick figures. MEK1 drug resistant mutations identified in the mutagenesis screen are color coded for primary mutations that are in the first (yellow) or second (orange) shell of AZD6244 drug binding or that are distal to the drug binding site (red). Helices A and C are also indicated. The three drug resistant mutations identified in the C-terminal kinase domain are not shown for clarity.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Mechanisms of drug resistance in kinases.
    Barouch-Bentov R, Sauer K. Barouch-Bentov R, et al. Expert Opin Investig Drugs. 2011 Feb;20(2):153-208. doi: 10.1517/13543784.2011.546344. Expert Opin Investig Drugs. 2011. PMID: 21235428 Free PMC article. Review.

References

    1. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009 - PMC - PubMed
    1. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263–84. - PMC - PubMed
    1. Smalley KS, Flaherty KT. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer. 2009;100:431–5. - PMC - PubMed
    1. Volpe G, Panuzzo C, Ulisciani S, Cilloni D. Imatinib resistance in CML. Cancer Lett. 2009;274:1–9. - PubMed
    1. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28–39. - PubMed

MeSH terms